According to the new market research report “Non-Invasive Prenatal Testing (NIPT) Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) – Global Forecast to 2021“, published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).
Don’t miss out on business opportunities in “Non Invasive Prenatal Testing Market”. Speak to our analyst and gain crucial industry insights that will help your business grow: http://bit.ly/2DgGbjd
Early buyers will receive 10% customization on reports.
The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016 at a CAGR of 16.4% during the forecast period. The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.
Market Dynamics
Drivers
- High risk of chromosomal abnormalities with increasing maternal age
- Growing preference for non-invasive techniques over invasive methods
- Launch of new and advanced products
- Improving reimbursement scenario for NIPT
- Programs focusing on increasing the awareness of NIPT
Restraints
- Lack of skilled professionals
Opportunities
- Untapped emerging markets
Challenges
- Reliability of test results especially in obese women
High risk of chromosomal abnormalities with increasing maternal age is a major driver for the market
Maternal age refers to the age of women at the time of delivery. Advancing maternal age can result in a number of health complications, such as decreased fertility and high blood pressure, and increase in the risk of miscarriage, stillbirths, and maternal death. Moreover, advancing maternal age can increase the risk of genetic disorders in babies as a result of the improper chromosomal division. The resulting abnormalities in babies may include microcephaly; short neck; upward slanted eyes; poor muscle tone; heart, intestine, and breathing problems; and other issues.
The impact of this factor is expected to increase across the globe as a result of the increase in average age of first-time mothers. Some of the important statistics in this regard have been mentioned below:
- In the U.S., around 10% of babies were born to first-time mothers at the age of 35 years or older, in 2016. Also, the median age of first-time mothers increased from 24.9 years in 2000 to 26.3 years in 2014 in the country (Source: CDC).
- According to Eurostat, in 2013, around 40.6% of women in the European Union who gave birth to their first child belonged to the age group of 30 years and above. Also, in the same year, around 65,500 births of first children were reported in women aged more than 40 years.
- According to Statistics Canada, in 2013, approximately 43% of births in the country were reported in women belonging to the age group of 30 to 49 years; in 1993, only 26% births were reported in women belonging to the same age group.
- In Australia, the average age of first-time mothers increased from 27.8 years in 2003 to 28.6 years in 2013 (Source: Australian Bureau of Statistics, 2015).
In order to detect genetic abnormalities resulting from improper chromosomal division, there is a growing demand for developing advanced and effective diagnostic procedures for early screening. Non-invasive prenatal testing is one such upcoming field which utilizes cell-free DNA in maternal plasma/fetal cells in maternal blood to determine genetic abnormalities. Thus, with the growing incidence of chromosomal abnormalities and benefits offered by NIPT, the demand for these tests is expected to increase in the coming years.
Browse and in-depth TOC on “Non Invasive Prenatal Testing Market”
110 – Tables
48 – Figures
150 – Pages
View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/non-invasive-prenatal-testing-market-145607690.html
The NIPT market is competitive in nature, with several major players competing for market space. Some of the prominent players in the market include Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), Beijing Genomics Institute (China), GE Healthcare (U.S.), and Koninklijke Philips N.V. (Netherlands).
Major Market Developments:
- In January 2017, Pacific Biosciences California, Inc. signed an agreement to supply Novogene Corporation, a provider of genomic and bioinformatics solutions, with ten sequel Systems for whole genome sequencing, Iso-sequence annotation, and target sequencing services
- In November 2016, GE Healthcare launched its ultrasound system—LOGIQ E9 XDclear 2.0 and showcased 25 new products at the Radiological Society of North America (RSNA) (U.S.). The showcased products included Senographe Pristina, SIGNA, DiscoveryMI and GSI Xtream on Revolution CT2, OptimaXR240amx, and other digital and software technologies. These products offer improved performance, productivity, and better clinical outcomes for clinicians and hospitals worldwide.
- In March 2016, Thermo Fisher Scientific acquired Affymetrix, Inc. (U.S.), a leading provider of life science and molecular diagnostic products. This acquisition enabled the company to strengthen its bioscience and genetic analysis capabilities.
Request for Free Sample Report @ http://bit.ly/2T6mr7p
Browse Adjacent Markets @ Biotechnology Market Research Reports & Consulting
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/non-invasive-prenatal-testing-market.asp
Visit Our Website: https://www.marketsandmarkets.com
